Xinhua Healthcare Signs an Exclusive License Agreement with ArcDia for its mariPOC Technology in China
Shots:
- Xinhua Healthcare to get exclusive license rights to commercialize ArcDia’s mariPOC platform in China. ArcDia to supply biochemical assay components and R&D services to Xinhua
- The focus of the collaboration is to expand Xinhua’s IVD business in point-of-care testing (POCT) and localize ArcDia’s mariPOC technology in addition to building up of a production capacity for decentralized infection diagnostic services in China
- ArcDia’s mariPOC IVD platform is an automated POC test system designed for the rapid multianalyte identification and detection of pathogens & inflammation markers focusses on respiratory tract infections- tonsillitis and gastroenteritis
Ref: ArcDia | Image: Twitter
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com